SHAREHOLDER ALERT: Goldberg Law PC Announces an Investigation of Endo International plc

Goldberg Law PC, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Endo International plc (“Endo” or the “Company”) (Nasdaq: ENDP).

If you purchased or otherwise acquired shares of Endo, and would like more information about the investigation, we encourage you to contact Michael Goldberg or Brian Schall, of Goldberg Law PC, 1999 Avenue of the Stars, Suite 1100, Los Angeles, CA 90067, at 800-977-7401, to discuss your rights without cost to you.

You can also reach us through the firm’s website at http://www.Goldberglawpc.com, or by email at info@goldberglawpc.com.

The investigation focuses on whether Endo and certain of its officers and/or directors violated federal securities laws. On June 8, 2017, the U.S. Food & Drug Administration (the “FDA”) requested that the Company pull its powerful opioid painkiller, Opana ER, off the market due to its “high risk of abuse and potential to help spread HIV and hepatitis C.” Following this news, Endo’s stock price dropped sharply.

If you have any questions about your legal rights, please immediately contact Goldberg Law PC at 800-977-7401, visit our website at http://www.Goldberglawpc.com, or email us at info@goldberglawpc.com.

Goldberg Law PC represents investors around the world, and specializes in securities class action lawsuits and shareholder rights litigation.

This press release may be considered Attorney Advertising in some jurisdictions under the applicable law and rules of ethics.

View source version on businesswire.com: http://www.businesswire.com/news/home/20170612006321/en/